The emerging role of mycophenolate mofetil in interstitial lung diseases

References

• Kreuter M, Herth FJF, Wacker M, et al. Exploring clinical and epidemiological characteristics of interstitial lung diseases: rationale, aims, and design of a nationwide prospective registry—The EXCITING-ILD registry. Biomed Res Int. 2015;2015:123876.
   PubMed Web of Science ®Google Scholar
• Richeldi L. Idiopathic pulmonary fibrosis: moving forward. BMC Med. 2015;13(1):231.
   PubMedGoogle Scholar
• Singh S, Collins BF, Sharma BB, et al. Interstitial lung disease in India. Results of a prospective registry. Am J Respir Crit Care Med. 2017;195(6):801–813.
   PubMed Web of Science ®Google Scholar
• Kundu S, Mitra S, Ganguly J, et al. Spectrum of diffuse parenchymal lung diseases with special reference to idiopathic pulmonary fibrosis and connective tissue disease: an eastern India experience. Lung India. 2014;31(4):354–360.
   PubMedGoogle Scholar
• Dhooria S, Agarwal R, Sehgal IS, et al. Spectrum of interstitial lung diseases at a tertiary center in a developing country: a study of 803 subjects. Plos One. 2018;13(2):e0191938.
   PubMedGoogle Scholar
• Boehringer Ingelheim Pharmaceuticals, Inc. (OFEV) nintedanib capsules for oral use. U.S. Food and Drug Administration [cited 2020 Jun 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/205832s012lbl.pdf
   Google Scholar
• European Medicines Agency. Esbriet: EPAR - Product information [updated 2020 Jan 30; cited 2020 Jun 25]. Available from: https://www.ema.europa.eu/en/documents/product-information/esbriet-epar-product-information_en.pdf
   Google Scholar
• Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718–1727.
   PubMed Web of Science ®Google Scholar
• Ueda T, Sakagami T, Kikuchi T, et al. Mycophenolate mofetil as a therapeutic agent for interstitial lung diseases in systemic sclerosis. Respir Investig. 2018;56(1):14–20.
   PubMed Web of Science ®Google Scholar
• Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47(2):85–118.
   PubMedGoogle Scholar
• Lipsky JJ. Mycophenolate mofetil. Lancet. 1996;348(9038):1357–1359.
   PubMed Web of Science ®Google Scholar
• Fulton B, Markham A. Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs. 1996;51(2):278–298.
   PubMedGoogle Scholar
• Roos N, Poulalhon N, Farge D, et al. In vitro evidence for a direct antifibrotic role of the immunosuppressive drug mycophenolate mofetil. J Pharmacol Exp Ther. 2007;321(2):583–589.
   PubMedGoogle Scholar
• Qiu Y, Fairbanks LD, Rückemann K, et al. Mycophenolic acid-induced GTP depletion also affects ATP and pyrimidine synthesis in mitogen-stimulated primary human T -lymphocytes. Transplantation. 2000;69(5):890–897.
   PubMedGoogle Scholar
• Taylor DO, Ensley RD, Olsen SL, et al. Mycophenolate mofetil (RS-61443): preclinical, clinical, and three-year experience in heart transplantation. J Heart Lung Transplant. 1994;13(4):571–582.
   PubMedGoogle Scholar
• Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal transplant mycophenolate mofetil study group. Transplantation. 1995;60(3):225–232.
   PubMed Web of Science ®Google Scholar
• Guo H, Leung JC, Chan LY, et al. Modulation of intra-pulmonary TGF-beta expression by mycophenolate mofetil in lupus prone MRL/lpr mice. Lupus. 2005;14(8):583–592.
   PubMedGoogle Scholar
• Morath C, Schwenger V, Beimler J, et al. Antifibrotic actions of mycophenolic acid. Clin Transplant. 2006;20(Suppl 17):25–29.
   PubMed Web of Science ®Google Scholar
• Morisset J, Johannson KA, Vittinghoff E, et al. Use of mycophenolate mofetil or azathioprine for the management of chronic hypersensitivity pneumonitis. Chest. 2017;151(3):619–625.
   PubMed Web of Science ®Google Scholar
• Fiddler CA, Simler N, Thillai M, et al. Use of mycophenolate mofetil and azathioprine for the treatment of chronic hypersensitivity pneumonitis—A single-centre experience. Clin Respir J. 2019;13(12):791–794.
   PubMedGoogle Scholar
• MacDonald D, Bhargava M, Tomic R, et al. Use of mycophenolate mofetil as a steroid-sparing agent in chronic hypersensitivity pneumonitis. Proceedings of the American Thoracic Society (ATS) International Conference; 2017 May 19-24; Washington, DC: American Thoracic Society; A1575.
   Google Scholar
• Adegunsoye A, Oldham JM, Fernández Pérez ER, et al. Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis. ERJ Open Res. 2017;3(3):00016–2017.
   PubMedGoogle Scholar
• Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016;4(9):708–719.
   PubMed Web of Science ®Google Scholar
• Owen C, Ngian GS, Elford K, et al. Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort Study. Clin Exp Rheumatol. 2016;34(Suppl 100(5)):170–176.
   PubMedGoogle Scholar
• Shenoy PD, Bavaliya M, Sashidharan S, et al. Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis. Arthritis Res Ther. 2016;18(1):123.
   PubMedGoogle Scholar
• Liossis SN, Bounas A, Andonopoulos AP. Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology (Oxford). 2006;45(8):1005–1008.
   PubMed Web of Science ®Google Scholar
• Gerbino AJ, Goss CH, Molitor JA. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest. 2008;133(2):455–460.
   PubMed Web of Science ®Google Scholar
• Highland KB, Distler O, Kuwana M, et al. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial. Lancet Respir Med. 2021;9(1):96–106.
   PubMed Web of Science ®Google Scholar
• Swigris JJ, Olson AL, Fischer A, et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest. 2006;130(1):30–36.
   PubMed Web of Science ®Google Scholar
• Fischer A, Brown KK, Du Bois RM, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol. 2013;40(5):640–646.
   PubMed Web of Science ®Google Scholar
• Santhanam S, Rahulan V. AB0803 A real life experience on the efficacy and safety of mycophenolate mofetil in connective tissue disorder associated interstitial lung disease – a retrospective study. Ann Rheum Dis. 2018;77:1533.
   Google Scholar
• Omair MA, Alhamad EH. Mycophenolate mofetil is an effective therapy for connective tissue disease-associated interstitial lung disease. Int J Clin Rheumatol. 2017;12(3):67.
   Google Scholar
• Saketkoo LA, Espinoza LR. Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects. Am J Med Sci. 2009;337(5):329–335.
   PubMed Web of Science ®Google Scholar
• Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, King TE Jr, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012;366(21):1968–1977.
   PubMed Web of Science ®Google Scholar
• Oldham JM, Lee C, Valenzi E, et al. Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease. Respir Med. 2016;121:117–122.
   PubMed Web of Science ®Google Scholar
• Amlani B, Elsayed G, Barvalia U, et al. Treatment of primary sjögren’s syndrome-related interstitial lung disease: a retrospective cohort study. Sarcoidosis Vasc Diffuse Lung Dis. 2020;37(2):136–147.
   PubMedGoogle Scholar
• Sara S, Mukadam Z, Meyer KC, et al. Mycophenolate therapy in interstitial pneumonia with autoimmune features: a cohort study. Ther Clin Risk Manag. 2018;14(1):2171–2181.
   PubMedGoogle Scholar
• Morganroth PA, Kreider ME, Werth VP. Mycophenolate mofetil for interstitial lung disease in dermatomyositis. Arthritis Care Res. 2010;62(10):1496–1501.
   PubMed Web of Science ®Google Scholar
• Mira-Avendano IC, Parambil JG, Yadav R, et al. A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis/dermatomyositis. Respir Med. 2013;107(6):890–896.
   PubMed Web of Science ®Google Scholar
• Koyama RVL, Braga TKK, da Silva Dias GA, et al. Hypomyopathic dermatomyositis associated with interstitial lung disease and good response to mycophenolate mofetil: case-based review. Clin Rheumatol. 2017;36(8):1919–1926.
   PubMedGoogle Scholar
• Huapaya JA, Silhan L, Pinal-Fernandez I, et al. Long-term treatment with azathioprine and mycophenolate mofetil for myositis-related interstitial lung disease. Chest. 2019;156(5):896–906.
   PubMed Web of Science ®Google Scholar
• Hanaoka H, Iida H, Kiyokawa T, et al. Mycophenolate mofetil treatment with or without a calcineurin inhibitor in resistant inflammatory myopathy. Clin Rheumatol. 2019;38(2):585–590.
   PubMedGoogle Scholar
• Kameda H, Takeuchi T. Recent advances in the treatment of interstitial lung disease in patients with polymyositis/dermatomyositis. Endocr Metab Immune Disord Drug Targets. 2006;6(4):409–415.
   PubMedGoogle Scholar
• Edge JC, Outland JD, Dempsey JR, et al. Mycophenolate Mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch Dermatol. 2006;142(1):65–69.
   PubMed Web of Science ®Google Scholar
• Papiris S, Stagaki E, Papadaki G, et al. Mycophenolate mofetil as an alternative treatment in sarcoidosis. Pulm Pharmacol Ther. 2019;58:101840.
   PubMedGoogle Scholar
• Stagaki E, Manali ED, Papadaki G, et al. Mycophenalate Mofetil as a corticosteroid-sparing agent in patients with sarcoidosis. Eur Respir J. 2018;52(suppl 62): PA4103.
   Google Scholar
• Brill AK, Ott SR, Geiser T. Effect and safety of mycophenolate mofetil in chronic pulmonary sarcoidosis: a retrospective study. Respiration. 2013;86(5):376–383.
   PubMed Web of Science ®Google Scholar
• Hamzeh N, Voelker A, Forssén A, et al. Efficacy of mycophenolate mofetil in sarcoidosis. Respir Med. 2014;108(11):1663–1669.
   PubMed Web of Science ®Google Scholar
• Nambiar AM, Anzueto AR, Peters JI. Effectiveness and safety of mycophenolate mofetil in idiopathic pulmonary fibrosis. Plos One. 2017;12(4):e0176312.
   PubMedGoogle Scholar
• Bjarnason I. Enteric coating of mycophenolate sodium: a rational approach to limit topical gastrointestinal lesions and extend the therapeutic index of mycophenolate. Transplant Proc. 2001;33(7–8):3238–3240.
   PubMedGoogle Scholar
• Sollinger H. Enteric-coated mycophenolate sodium: therapeutic equivalence to mycophenolate mofetil in de novo renal transplant patients. Transplant Proc. 2004;36(2Suppl):517S–520S.
   PubMedGoogle Scholar
• Baughman RP, Meyer KC, Nathanson I, et al. Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;142(5):e1S–e111S.
   PubMed Web of Science ®Google Scholar
• Wolfe EJ, Mathur V, Tomlanovich S, et al. Pharmacokinetics of mycophenolate mofetil and intravenous ganciclovir alone and in combination in renal transplant recipients. Pharmacotherapy. 1997;17(3):591–598.
   PubMed Web of Science ®Google Scholar
• Gene.com. [Internet]. South San Francisco (CA): Genentech US Drug Safety; [Cited 2021 Jun 5]. Available from: https://www.gene.com/download/pdf/cellcept_prescribing.pdf
   Google Scholar
• Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354(25):2655–2666.
   PubMed Web of Science ®Google Scholar
• Wong AW, Donohoe K, Marcoux. V, et al. Tolerability of mycophenolate and azathioprine in patients with fibrotic interstitial lung disease: a prospective cohort study using real-world data. Proceedings of the American Thoracic Society (ATS) International conference; 2021 May 14-19; virtual conference: American Thoracic Society; A1914
   Google Scholar